We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice.
- Authors
Emamaullee, Juliet A; Davis, Joy; Pawlick, Rena; Toso, Christian; Merani, Shaheed; Cai, Sui-Xiong; Tseng, Ben; Shapiro, A M James
- Abstract
Clinical islet transplantation can provide insulin independence in patients with type 1 diabetes, but chronic graft failure has been observed. This has been attributed in part to loss of >or=60% of the transplanted islets in the peritransplant period, resulting in a marginal implant mass. Strategies designed to maximize survival of the initial islet mass are likely to have major impact in enhancing long-term clinical outcomes. EP1013 (N-benzyloxycabonyl-Val Asp-fluoromethyl ketone [zVD-FMK]), is a broad-spectrum caspase selective inhibitor with no observed toxicity in rodents.
- Publication
Diabetes, 2008, Vol 57, Issue 6, p1556
- ISSN
1939-327X
- Publication type
Journal Article
- DOI
10.2337/db07-1452